JNK pathway: Diseases and therapeutic potential

Acta Pharmacologica Sinica

Volumn 28, Issue 5, 2007, Pages 601-608

  Cui, Jie ^a,b   Zhang, Ming ^a,b   Zhang, Yong Qing ^a   Xu, Zhi Heng ^a  

^a INSTITUTE OF GENETICS AND DEVELOPMENTAL BIOLOGY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

Diseases; Inhibitors; JNK pathway; Signal transduction

Indexed keywords

1,3 BENZOTHIAZOL 2 YL[2 [[2 (3 PYRIDINYL)ETHYL]AMINO] 4 PYRIDINYL]ACETONITRILE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; AS 601245; CEP 1347; PROTEIN C JUN; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG;

APOPTOSIS; CLINICAL TRIAL; DRUG TARGETING; ENZYME ACTIVITY; FUNCTIONAL PROTEOMICS; HUMAN; LOW DRUG DOSE; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; STROKE;

ANIMALS; DISEASE; ENZYME INHIBITORS; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MAP KINASE SIGNALING SYSTEM;

EID: 34247580832     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2007.00579.x     Document Type: Review

References (75)

1. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell 2000 103 : 239 5.
2. Weston CR, Davis RJ. The JNK signal transduction pathway. Curr Opin Genet Dev 2002 12 : 14 21.
3. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001 22 : 153 83.
4. Nakatani Y, Kaneto H, Kawamori D, Hatazaki M, Miyatsuka T, Matsuoka TA, et al. Modulation of the JNK pathway in liver affects insulin resistance status. J Biol Chem 2004 279 : 45803 9.
5. Manning AM, Davis RJ. Targeting JNK for therapeutic benefit: from junk to gold Nat Rev Drug Discov 2003 2 : 554 65.
6. Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 2001 81 : 807 69.
7. Kyriakis JM, Avruch, J. pp54 microtubule-associated protein 2 kinase. A novel serine/threonine protein kinase regulated by phosphorylation and stimulated by poly-L-lysine. J Biol Chem 1990 265 : 17355 63.
8. Kyriakis JM, Banerjee, P, Nikolakaki E, Dai T, Rubie EA, Ahmad MF, et al. The stress-activated protein kinase subfamily of c-Jun kinase. Nature 1994 369 : 156 60.
9. Ichijo H. From receptors to stress-activated MAP kinase. Oncogene 1999 18 : 6087 93.
10. Yang DD, Kuan CY, Whitmarsh AJ, Rincon M, Zheng TS, Davis RJ, et al. Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene. Nature 1997 389 : 865 70.
11. Maroney AC, Finn JP, Bozyczko-Coyne D, O'Kane TM, Neff NT, Tolkovsky AM, et al. CEP-1347 (KT7515), an inhibitor of JNK activation, rescues sympathetic neurons and neuronally differentiated PC 12 cells from death evoked by three distinct insults. J Neurochem 1999 73 : 1901 12.
12. Troy CM, Rabacchi SA, Xu Z, Maroney AC, Connors TJ, Shelanski ML, et al. Beta-amyloid-induced neuronal apoptosis requires c-Jun N-terminal kinase activation. J Neurochem 2001 77 : 157 64.
13. Trotter L, Panton W, Hajimohamadreza I, Petalidis L, Ward R, Fleming Y, et al. Mitogen-activated protein kinase kinase 7 is activated during low potassium-induced apoptosis in rat cerebellar granule neurons. Neurosci Lett 2002 320 : 29 32.
14. Xu Z, Kukekov NV, Greene LA. POSH acts as a scaffold for a multiprotein complex that mediates JNK activation in apoptosis. EMBO J 2003 15 22 : 252 61.
15. Xu Z, Kukekov NV, Greene LA. Regulation of apoptotic c-Jun N-terminal kinase signaling by a stabilization-based feed-forward loop. Mol Cell Biol 2005 25 : 9949 59.
16. Xu Z, Sproul A, Wang W, Kukekov N, Greene LA. Siah1 interacts with the scaffold protein POSH to promote JNK activation and apoptosis. J Biol Chem 2006 281 : 303 12.
17. Xu Z, Greene LA. Activation of the apoptotic JNK pathway through the Rac1-binding scaffold protein POSH. Methods Enzymol 2006 406 : 479 89.
18. Wilhelm M, Xu Z, Kukekov NV, Gire S, Greene LA. Proapoptotic Nix activates the JNK pathway by interacting with POSH and mediates death in a Parkinson disease model. J Biol Chem 2006 [Epub ahead of print].
19. Xu Z, Maroney AC, Dobrzanski P, Kukekov NV, Greene LA. The MLK family mediates c-Jun N-terminal kinase activation in neuronal apoptosis. Mol Cell Biol 2001 4713 24.
20. Dickens M, Rogers JS, Cavanagh J, Raitano A, Xia Z, Halpern JR, et al. A cytoplasmic inhibitor of the JNK signaling transduction pathway. Science 1997 277 : 693 6.
21. Kukekov NV, Xu Z, Greene LA. Direct interaction of the molecular scaffolds POSH and JIP is required for apoptotic activation of JNKs. J Biol Chem 2006 281 : 15517 24.
22. Gupta S, Barrett T, Whitmarsh AJ, Cavanagh J, Sluss HK, Derijard B, et al. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J 1996 15 : 2760 70.
23. Derijard B, Hibi M, Wu IH, Barrett T, Su B, Deng T, et al. JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 1994 76 : 1025 37.
24. Gupta S, Campbell D, Derijard B, Davis RJ. Transcription factor ATF2 regulation by the JNK signal transduction pathway. Science 1995 267 : 389 93.
25. Yang DD, Conze D, Whitmarsh AJ, Barrett T, Davis RJ, Rincon M, et al. Differentiation of CD4+ T cells to Th1 cells requires MAP kinase JNK2. Immunity 1998 9 : 575 85.
26. Chow CW, Rico MN, Cavanagh J, Dickens M, Davis RJ. Nuclear accumulation of NFAT4 opposed by the JNK signaling pathway. Science 1997 278 : 1638 41.
27. Buschmann T, Potapova O, Bar-Shira A, Ivanov VN, Fuchs SY, Henderson S, et al. Jun NH2-terminal kinase phosphorylation of p53 on Thr-81 is important for p53 stabilization and transcription activities in response to stress. Mol Cell Biol 2001 21 : 2743 54.
28. Tournier C, Hess P, Yang DD, Xu J, Turner TK, Nimnual A, et al. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science 2000 288 : 870 4.
29. Maundrell K, Antonsson B, Magnenat E, Camps M, Muda M, Chabert C, et al. Bcl-2 undergoes phosphorylation by c-Jun N-terminal kinase/stress-activated protein kinases in the presence of the constitutively active GTP-binding protein Rac1. J Biol Chem 1997 272 : 25238 42.
30. Yamamoto K, Ichijo H, Korsmeyer SJ. BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol cell Biol 1999 19 : 8469 78.
31. Kharbanda S, Saxena S, Yoshida K, Pandey P, Kaneki M, Wang Q, et al. Translocation of SAPK/JNK to mitochondria and interaction with Bcl-x(L) in response to DNA damage. J Biol Chem 2000 275 : 322 7.
32. Donovan N, Becker EB, Konishi Y, Bonni A. JNK phosphorylation and activation of BAD couples the stress-activated signaling pathway to the cell death machinery. J Biol Chem 2002 277 : 40944 9.
33. Lei K, Davis RJ. JNK phosphorylation of Bim-related members of the Bcl-2 family induces Bax-dependent apoptosis. Proc Natl Acad Sci USA 2003 100 : 2432 7.
34. Ferrer I, Gomez-Isla T, Puig B, Freixes M, Ribe E, Dalfo E, et al. Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies. Curr Alzheimer Res 2005 2 : 3 18.
35. Savage MJ, Lin YG, Ciallella JR, Flood DG, Scott RW, et al. Activation of c-Jun N-terminal kinase and p38 in an Alzheimer's disease model is associated with amyloid deposition. J Neurosci 2002 22 : 3376 85.
36. Smith WW, Gorospe M, Kusiak JW. Signaling mechanisms underlying Abeta toxicity: potential therapeutic targets for Alzheimer's disease. CNS Neurol Disord Drug Targets 2006 5 : 355 61.
37. Hunot S, Vila M, Teismann P, Davis RJ, Hirsch EC, Przedborski S, et al. JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. Proc Natl Acad Sci USA 2004 101 : 665 70.
38. Xia XG, Harding T, Weller M, Bieneman A, Uney JB, Schulz JB. Gene transfer of the JNK interacting protein-1 protects dopam-inergic neurons in the MPTP model of Parkinson's disease. Proc Natl Acad Sci USA 2001 98 : 10433 8.
39. Kuan CY, Burke RE. Targeting the JNK signaling pathway for stroke and Parkinson's diseases therapy. Curr Drug Targets CNS Neurol Disord 2005 4 : 63 7.
40. Herdegen T, Claret FX, Kallunki T, Martin-Villalba A, Winter C, Hunter T, et al. Lasting N-terminal phosphorylation of c-Jun and activation of c-Jun N-terminal kinases after neuronal injury. J Neurosci 1998 18 : 5124 35.
41. Kuan CY, Whitmarsh AJ, Yang DD, Liao G, Schloemer AJ, Dong C, et al. A critical role of neural-specific JNK3 for ischemic apoptosis. Proc Natl Acad Sci USA 2003 100 : 15184 9.
42. Whitmarsh, AJ, Kuan CY, Kennedy NJ, Kelkar N, Haydar TF, Mordes JP, et al. Requirement of the JIP1 scaffold protein for stress-induced JNK activation. Genes Dev 2001 15 : 2421 32.
43. Im JY, Lee KW, Kim MH, Lee SH, Ha HY, Cho IH, et al. Repression of phospho-JNK and infarct volume in ischemic brain of JIP 1-deficient mice. J Neurosci Res 2003 74 : 326 32.
44. Zhang QG, Wang RM, Yin XH, Pan J, Xu TL, Zhang GY. Knockdown of POSH expression is neuroprotective through down-regulating activation of the MLK3-MKK4-JNK pathway following cerebral ischaemia in the rat hippocampal CA1 subfield. J Neurochem 2005 95 : 784 95.
45. Chen YR, Meyer CF, Tan TH. Persistent activation of c-Jun N-terminal kinase 1 (JNK1) in radiation-induced apoptosis. J Biol Chem 1996 27 : 631 4.
46. Kaneto H, Nakatani Y, Kawamori D, Miyatsuka T, Matsuoka TA, Matsuhisa M, et al. Role of oxidative stress, endoplasmic reticulum stress, and c-Jun N-terminal kinase in pancreatic beta-cell dysfunction and insulin resistance. Int J Biochem Cell Biol 2006 38 : 782 93.
47. Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K, et al. Hotanisligil, a central role for JNK in obesity and insulin resistance. Nature 2002 420 : 333 6.
48. Aguirre V, Uchida T, Yenush L, Davis R, White MF. The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem 2000 275 : 9047 54.
49. Jaeschke A, Czech MP, Davis RJ. An essential role of the JIP1 scaffold protein for JNK activation in adipose tissue. Genes Dev 2004 18 : 1976 80.
50. Waeber G, Delplanque J, Bonny C, Mooser V, Steinmann M, Widmann C, et al. The gene MAPK8IP1, encoding islet-brain-1, is a candidate for type 2 diabetes. Nat Genet 2000 24 : 291 5.
51. Ammendrup A, Maillard A, Nielsen K, Aabenhus Andersen N, Serup P, Dragsbaek Madsen O, et al. The c-Jun amino-terminal kinase pathway is preferentially activated by interleukin-1 and controls apoptosis in differentiating pancreatic beta-cells. Diabetes 2000 49 : 1468 76.
52. Bonny A, Oberson S, Negri C, Sauser X, Schorderet DF. Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death. Diabetes 2001 50 : 77 82.
53. Abdelli S, Ansite J, Roduit R, Borsello T, Matsumoto I, Sawada T, et al. Intracellular stress signaling pathways activated during human islet preparation and following acute cytokine exposure. Diabetes 2004 53 : 2815 23.
54. Kaneto H, Xu G, Fujii N, Kim S, Bonner-Weir S, Weir GC. Involvement of c-Jun N-terminal kinase in oxidative stress-mediated suppression of insulin gene expression. J Biol Chem 2002 277 : 30010 8.
55. Bennett BL, Satoh Y, Lewis AJ. JNK: a new therapeutic target for diabetes. Curr Opin Pharmacol 2003 3 : 420 5.
56. Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W, et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA 2001 98 : 13681 6.
57. Kaneko M, Saito Y, Saito H, Matsumoto T, Matsuda Y, Vaught JL, et al. Neurotrophic 3,9-bis[(alkylthio)methyl]-and-bis (alkoxymethyl)-K-252a derivatives. J Med Chem 1997 40 : 1863 9.
58. Kase H, Iwahashi K, Matsuda Y. K-252a, a potent inhibitor of protein kinase C from microbial origin. J Antibiot (Tokyo) 1986 39 : 1059 65.
59. Maroney AC, Glicksman MA, Basma AN, Walton KM, Knight E, Murphy CA, et al. Motoneuron apoptosis is blocked by CEP-1347 (KT7515), a novel inhibitor of the JNK signaling pathway. J Neurosci 1998 18 : 104 11.
60. Saporito MS, Brown EM, Miller MS, Carswell S. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons in vivo. J Pharmacol Exp Ther 1999 288 : 421 7.
61. Teismann P, Tieu K, Choi DK, Wu DC, Naini A, Hunot S, et al. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci USA 2003 100 : 54 73.
62. Pirvola U, Liang XQ, Virkkala J, Saarma M, Murakata C, Camoratto AM, et al. Rescue of hearing, auditory hair cells, and neurons by CEP-1347/KT7515, an inhibitor of c-Jun N-terminal kinase activation. J Neurosci 2000 20 : 43 50.
63. Ylikoski J, Liang XQ, Virkkala J, Pirvola U. Blockade of c-Jun N-terminal kinase pathway attenuates gentamicin-induced co-chlear and vestibular hair cell death. Hear Res 2002 166 : 33 43.
64. Wagner AC, Mazzucchelli L, Miller M, Camoratto AM, Goke B. CEP-13 47 inhibits caerulein-induced rat pancreatic JNK activation and ameliorates caerulein pancreatitis. Am J Physiol Gastrointest Liver Physiol 2000 278 : G165 72.
65. Hashimoto S, Gon Y, Takeshita I, Maruoka S, Horie T. IL-4 and IL-13 induce myofibroblastic phenotype of human lung fibro-blasts through c-Jun NH2-terminal kinase-dependent pathway. J Allergy Clin Immunol 2001 107 : 1001 8.
66. Maroney AC, Finn JP, Connors TJ, Ddurkin JT, Angeles T, Gessner G, et al. CEP-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage kinase family. J Biol Chem 2001 276 : 25 302 8.
67. Wang W, Shi L, Xie L, Ma C, Li W, Su X, et al. SP600125, a new JNK inhibitor, protects dopaminergic neurons in the MPTP model of Parkinson's disease. Neurosci Res 2004 48 : 195 202.
68. Chialda L, Zhang M, Brune K, Pahl A. Inhibitors of mitogen-activated protein kinases differentially regulate costimulated T cell cytokine production and mouse airway eosinophilia. Respir Res 2005 15 : 6 36.
69. Carboni S, Hiver A, Szyndralewiez C, Gaillard P, Gotteland JP, Vitte PA. AS601245 (1,3-benzothiazol-2-yl (2-[[2-(3-pyridinyl) ethyl] amino]-4 pyrimidinyl) acetonitrile): a c-Jun NH2-terminal protein kinase inhibitor with neuroprotective properties. J Pharmacol Exp Ther 2004 301 : 25 32.
70. Carboni S, Antonsson B, Gaillard P, Gotteland JP, Gillon JY, Vitte PA. Control of death receptor and mitochondrial-dependent apoptosis by c-Jun N-terminal kinase in hippocampal CA1 neurons following global transient ischaemia. J Neurochem 2005 92 : 1054 60.
71. Ferrandi C, Ballerio R, Gaillard P, Giachetti C, Carboni S, Vitte PA, et al. Inhibition of c-Jun N-terminal kinase decreases cardiomyocyte apoptosis and infarct size after myocardial ischemia and reperfusion in anaesthetized rats. Br J Pharmacol 2004 142 : 953.
72. Gaillard P, Jeanclaude-Etter I, Ardissone V, Arkinstall S, Cambet Y, Camps M, et al. Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase. J Med Chem 2005 48 : 4596 607.
73. Barr RK, Kendrick TS, Bogoyevitch MA. Identification of the critical features of a small peptide inhibitor of JNK activity. J Biol Chem 2002 277 : 10 987 97.
74. Wang J, van De Water TR, Bonny C, De Ribaupierre F, Puel JL, Zine A. A peptide inhibitor of c-Jun N-terminal kinase protects against both aminoglycoside and acoustic trauma-induced auditory hair cell death and hearing loss. J Neurosci 2003 23 : 8596 607.
75. Hirt L, Badaut J, Thevenet J, Granziera C, Regli L, Maurer F, et al. D-JNKI1, a cell-penetrating c-Jun-N-terminal kinase inhibitor, protects against cell death in severe cerebral ischemia. Stroke 2004 35 : 1738 43.